Cingulate releases pharmacokinetic study for ADHD drug candidate
Results from the Phase I trial support further development of CTx-1301, a novel treatment for attention deficit hyperactivity disorder.
Cingulate Inc. on Monday announced the publication of a pharmacokinetic study evaluating CTx-1301, its investigational drug candidate for attention deficit hyperactivity disorder (ADHD).
The Phase I trial assessed the drug’s absorption, distribution, metabolism and excretion in healthy volunteers, providing data on dosing, safety and tolerability. Cingulate said the results support the continued development of CTx-1301, which is designed as a once-daily, extended-release treatment.
The study’s findings were published in a peer-reviewed scientific journal, though Cingulate did not disclose specific numerical data in its announcement. The company plans to advance CTx-1301 into further clinical trials as part of its broader pipeline of CNS-focused therapies.
ADHD treatments currently on the market include stimulants such as methylphenidate and amphetamines, as well as non-stimulants like atomoxetine. Cingulate’s candidate aims to offer an alternative with a differentiated pharmacokinetic profile, potentially improving patient adherence and reducing side effects.
Cingulate is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →